Alloreactive natural killer cells in hematopoietic stem cell transplantation

Leukemia Research

Volumn 35, Issue 1, 2011, Pages 14-21

  Pegram, Hollie J ^a   Ritchie, David S ^a   Smyth, Mark J ^a,b   Wiernik, Andres ^c,d   Prince, H Miles ^a   Darcy, Phillip K ^a,b,e   Kershaw, Michael H ^a,b,e  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MINNESOTA   (United States)

^d HENNEPIN COUNTY MEDICAL CENTER   (United States)

^e MONASH UNIVERSITY   (Australia)

Author keywords

Acute myeloid leukemia; Allogeneic stem cell transplantation; Graft versus host disease; Graft versus leukemia; Immunotherapy; KIR

Indexed keywords

KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; DISEASE FREE SURVIVAL; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; LEUKEMIA RELAPSE; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; T LYMPHOCYTE;

GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KILLER CELLS, NATURAL; RECEPTORS, KIR;

EID: 78650170200     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.07.030     Document Type: Review

References (79)

1. Martelli M.F., Aversa F., Bachar-Lustig E., Velardi A., Reich-Zelicher S., Tabilio A., et al. Transplants across human leukocyte antigen barriers. Semin Hematol 2002, 39(January (1)):48-56.
2. Aversa F., Tabilio A., Terenzi A., Velardi A., Falzetti F., Giannoni C., et al. Successful engraftment of T-cell-depleted haploidentical " three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994, 84(December (11)):3948-3955.
3. Aversa F., Terenzi A., Tabilio A., Falzetti F., Carotti A., Ballanti S., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005, 23(May (15)):3447-3454.
4. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295(March (5562)):2097-2100.
5. Kiessling R., Klein E., Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975, 5(February (2)):112-117.
6. Ciccone E., Pende D., Viale O., Di Donato C., Tripodi G., Orengo A.M., et al. Evidence of a natural killer (NK) cell repertoire for (allo) antigen recognition: definition of five distinct NK-determined allospecificities in humans. J Exp Med 1992, 175(March (3)):709-718.
7. Colonna M., Brooks E.G., Falco M., Ferrara G.B., Strominger J.L. Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C. Science 1993, 260(May (5111)):1121-1124.
8. Husain Z., Alper C.A., Yunis E.J., Dubey D.P. Complex expression of natural killer receptor genes in single natural killer cells. Immunology 2002, 106(July (3)):373-380.
9. Raulet D.H. Interplay of natural killer cells and their receptors with the adaptive immune response. Nat Immunol 2004, 5(October (10)):996-1002.
10. Fauriat C., Andersson S., Bjorklund A.T., Carlsten M., Schaffer M., Bjorkstrom N.K., et al. Estimation of the size of the alloreactive NK cell repertoire: studies in individuals homozygous for the group A KIR haplotype. J Immunol 2008, 181(November (9)):6010-6019.
11. Yawata M., Yawata N., Draghi M., Partheniou F., Little A.M., Parham P. MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood 2008, 112(September (6)):2369-2380.
12. Kim S., Poursine-Laurent J., Truscott S.M., Lybarger L., Song Y.J., Yang L., et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005, 436(August (7051)):709-713.
13. Jonsson A.H., Yokoyama W.M. Natural killer cell tolerance licensing and other mechanisms. Adv Immunol 2009, 101:27-79.
14. Yu J., Venstrom J.M., Liu X.R., Pring J., Hasan R.S., O'Reilly R.J., et al. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation. Blood 2009, 113(April (16)):3875-3884.
15. Moretta A., Bottino C., Pende D., Tripodi G., Tambussi G., Viale O., et al. Identification of four subsets of human CD3-CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition. J Exp Med 1990, 172(December (6)):1589-1598.
16. Moretta L., Moretta A. Killer immunoglobulin-like receptors. Curr Opin Immunol 2004, 16(October (5)):626-633.
17. Gasser S., Raulet D.H. Activation and self-tolerance of natural killer cells. Immunol Rev 2006, 214(December):130-142.
18. Ruggeri L., Mancusi A., Capanni M., Urbani E., Carotti A., Aloisi T., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007, 110(July (1)):433-440.
19. Giebel S., Locatelli F., Lamparelli T., Velardi A., Davies S., Frumento G., et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003, 102(August (3)):814-819.
20. Kawase T., Matsuo K., Kashiwase K., Inoko H., Saji H., Ogawa S., et al. HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism. Blood 2009, 113(March (12)):2851-2858.
21. Clausen J., Wolf D., Petzer A.L., Gunsilius E., Schumacher P., Kircher B., et al. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Immunol 2007, 148(June (3)):520-528.
22. Willemze R., Rodrigues C.A., Labopin M., Sanz G., Michel G., Socie G., et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009, 23(March (3)):492-500.
23. Pende D., Marcenaro S., Falco M., Martini S., Bernardo M.E., Montagna D., et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009, 113(March (13)):3119-3129.
24. Mengarelli A., Zarcone D., Caruso R., Tenca C., Rana I., Pinto R.M., et al. Adhesion molecule expression, clinical features and therapy outcome in childhood acute lymphoblastic leukemia. Leuk Lymphoma 2001, 40(February (5-6)):625-630.
25. Hsu K.C., Gooley T., Malkki M., Pinto-Agnello C., Dupont B., Bignon J.D., et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2006, 12(August (8)):828-836.
26. Brunstein C.G., Wagner J.E., Weisdorf D.J., Cooley S., Noreen H., Barker J.N., et al. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood 2009, 113(May (22)):5628-5634.
27. Davies S.M., Ruggieri L., DeFor T., Wagner J.E., Weisdorf D.J., Miller J.S., et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 2002, 100(November (10)):3825-3827.
28. Andersson S., Fauriat C., Malmberg J.A., Ljunggren H.G., Malmberg K.J. KIR acquisition probabilities are independent of self-HLA class I ligands and increase with cellular KIR expression. Blood 2009, 114(July (1)):95-104.
29. Ljunggren H.G., Malmberg K.J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 2007, 7(May (5)):329-339.
30. Hoglund P., Glas R., Ohlen C., Ljunggren H.G., Karre K. Alteration of the natural killer repertoire in H-2 transgenic mice: specificity of rapid lymphoma cell clearance determined by the H-2 phenotype of the target. J Exp Med 1991, 174(August (2)):327-334.
31. Raulet D.H., Vance R.E., McMahon C.W. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol 2001, 19:291-330.
32. McQueen K.L., Parham P. Variable receptors controlling activation and inhibition of NK cells. Curr Opin Immunol 2002, 14(October (5)):615-621.
33. Gumperz J.E., Valiante N.M., Parham P., Lanier L.L., Tyan D. Heterogeneous phenotypes of expression of the NKB1 natural killer cell class I receptor among individuals of different human histocompatibility leukocyte antigens types appear genetically regulated, but not linked to major histocompatibililty complex haplotype. J Exp Med 1996, 183(April (4)):1817-1827.
34. Frohn C., Schlenke P., Kirchner H. The repertoire of HLA-Cw-specific NK cell receptors CD158 a/b (EB6 and GL183) in individuals with different HLA phenotypes. Immunology 1997, 92(December (4)):567-570.
35. Vilches C., Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 2002, 20:217-251.
36. Fernandez N.C., Treiner E., Vance R.E., Jamieson A.M., Lemieux S., Raulet D.H. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 2005, 105(June (11)):4416-4423.
37. Leung W., Iyengar R., Triplett B., Turner V., Behm F.G., Holladay M.S., et al. Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 2005, 174(May (10)):6540-6545.
38. Chan H.W., Kurago Z.B., Stewart C.A., Wilson M.J., Martin M.P., Mace B.E., et al. DNA methylation maintains allele-specific KIR gene expression in human natural killer cells. J Exp Med 2003, 197(January (2)):245-255.
39. Gardiner C.M., Guethlein L.A., Shilling H.G., Pando M., Carr W.H., Rajalingam R., et al. Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. J Immunol 2001, 166(March (5)):2992-3001.
40. Santourlidis S., Trompeter H.I., Weinhold S., Eisermann B., Meyer K.L., Wernet P., et al. Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells. J Immunol 2002, 169(October (8)):4253-4261.
41. Shilling H.G., Guethlein L.A., Cheng N.W., Gardiner C.M., Rodriguez R., Tyan D., et al. Allelic polymorphism synergizes with variable gene content to individualize human KIR genotype. J Immunol 2002, 168(March (5)):2307-2315.
42. Pende D., Spaggiari G.M., Marcenaro S., Martini S., Rivera P., Capobianco A., et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 2005, 105(March (5)):2066-2073.
43. Flomenberg N., Baxter-Lowe L.A., Confer D., Fernandez-Vina M., Filipovich A., Horowitz M., et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004, 104(October (7)):1923-1930.
44. Petersdorf E.W., Hansen J.A., Martin P.J., Woolfrey A., Malkki M., Gooley T., et al. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med 2001, 345(December (25)):1794-1800.
45. Petersdorf E.W., Longton G.M., Anasetti C., Mickelson E.M., McKinney S.K., Smith A.G., et al. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood 1997, 89(March (5)):1818-1823.
46. Ruggeri L., Mancusi A., Burchielli E., Aversa F., Martelli M.F., Velardi A. Natural killer cell alloreactivity in allogeneic hematopoietic transplantation. Curr Opin Oncol 2007, 19(March (2)):142-147.
47. Leung W., Iyengar R., Turner V., Lang P., Bader P., Conn P., et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004, 172(January (1)):644-650.
48. Ruggeri L., Mancusi A., Capanni M., Martelli M.F., Velardi A. Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr Opin Immunol 2005, 17(April (2)):211-217.
49. Hansasuta P., Dong T., Thananchai H., Weekes M., Willberg C., Aldemir H., et al. Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur J Immunol 2004, 34(June (6)):1673-1679.
50. Cohen J.M., Cooper N., Chakrabarti S., Thomson K., Samarasinghe S., Cubitt D., et al. EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning. Leuk Lymphoma 2007, 48(February (2)):256-269.
51. Shaw B.E., Gooley T.A., Malkki M., Madrigal J.A., Begovich A.B., Horowitz M.M., et al. The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. Blood 2007, 110(December (13)):4560-4566.
52. Morishima Y., Yabe T., Matsuo K., Kashiwase K., Inoko H., Saji H., et al. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor. Biol Blood Marrow Transplant 2007, 13(March (3)):315-328.
53. Kroger N., Binder T., Zabelina T., Wolschke C., Schieder H., Renges H., et al. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation 2006, 82(October (8)):1024-1030.
54. Venstrom J.M., Gooley T.A., Spellman S., Pring J., Malkki M., Dupont B., et al. Donor activating KIR3DS1 is associated with decreased acute GvHD in unrelated allogeneic hematopoietic stem cell transplantation. Blood 2010, (February (1)).
55. Verheyden S., Schots R., Duquet W., Demanet C. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 2005, 19(August (8)):1446-1451.
56. Cooley S., Trachtenberg E., Bergemann T.L., Saeteurn K., Klein J., Le C.T., et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009, 113(January (3)):726-732.
57. Zaia J.A., Sun J.Y., Gallez-Hawkins G.M., Thao L., Oki A., Lacey S.F., et al. The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009, 15(March (3)):315-325.
58. Stringaris K, Adams S, Uribe M, Eniafe R, Wu CO, Savani BN, et al. Donor KIR genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukaemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukaemia but not other haematological malignancies. Biol Blood Marrow Transplant 2010; Epub March 16.
59. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., McNearney S.A., Yun G.H., Fautsch S.K., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105(April (8)):3051-3057.
60. Berg M., Lundqvist A., McCoy P., Samsel L., Fan Y., Tawab A., et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009, 11(3):341-355.
61. Miller J.S. Should natural killer cells be expanded in vivo or ex vivo to maximize their therapeutic potential?. Cytotherapy 2009, 11:259-260.
62. Romagne F., Andre P., Spee P., Zahn S., Anfossi N., Gauthier L., et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009, 114(September (13)):2667-2677.
63. Sola C., Andre P., Lemmers C., Fuseri N., Bonnafous C., Blery M., et al. Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci USA 2009, 106(August (31)):12879-12884.
64. Smyth M.J., Cretney E., Kershaw M.H., Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004, 202(December):275-293.
65. Gattinoni L., Powell D.J., Rosenberg S.A., Restifo N.P. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006, 6(May (5)):383-393.
66. Nguyen S., Kuentz M., Vernant J.P., Dhedin N., Bories D., Debre P., et al. Involvement of mature donor T cells in the NK cell reconstitution after haploidentical hematopoietic stem-cell transplantation. Leukemia 2008, 22(February (2)):344-352.
67. Elmaagacli A.H., Ottinger H., Koldehoff M., Peceny R., Steckel N.K., Trenschel R., et al. Reduced risk for molecular disease in patients with chronic myeloid leukemia after transplantation from a KIR-mismatched donor. Transplantation 2005, 79(June (12)):1741-1747.
68. Beelen D.W., Ottinger H.D., Ferencik S., Elmaagacli A.H., Peceny R., Trenschel R., et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 2005, 105(March (6)):2594-2600.
69. Farag S.S., Bacigalupo A., Eapen M., Hurley C., Dupont B., Caligiuri M.A., et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant 2006, 12(August (8)):876-884.
70. Bishara A., De Santis D., Witt C.C., Brautbar C., Christiansen F.T., Or R., et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 2004, 63(March (3)):204-211.
71. Bornhauser M., Schwerdtfeger R., Martin H., Frank K.H., Theuser C., Ehninger G. Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 2004, 103(April (7)):2860-2861. author reply 2862.
72. Lowe E.J., Turner V., Handgretinger R., Horwitz E.M., Benaim E., Hale G.A., et al. T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation. Br J Haematol 2003, 123(October (2)):323-326.
73. Stern M., Ruggeri L., Mancusi A., Bernardo M.E., de Angelis C., Bucher C., et al. Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood 2008, 112(October (7)):2990-2995.
74. Bjorklund A.T., Schaffer M., Fauriat C., Ringden O., Remberger M., Hammarstedt C., et al. NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation. Blood 2010, 115(April (13)):2686-2694.
75. Smyth M.J., Teng M.W., Swann J., Kyparissoudis K., Godfrey D.I., Hayakawa Y. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 2006, 176(February (3)):1582-1587.
76. Rezvani K., Mielke S., Ahmadzadeh M., Kilical Y., Savani B.N., Zeilah J., et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006, 108(August (4)):1291-1297.
77. Ferrara J.L., Deeg H.J. Graft-versus-host disease. N Engl J Med 1991, 324(March (10)):667-674.
78. Rubnitz J.E., Inaba H., Ribeiro R.C., Pounds S., Rooney B., Bell T., et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010, 28(20 February (6)):955-959.
79. Schaffer M., Malmberg K.J., Ringden O., Ljunggren H.G., Remberger M. Increased infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation. Transplantation 2004, 78(October (7)):1081-1085.